title: Cellular vaccines.
abstract: This project is devoted to the development of novel cellular vaccines designed to treat cancer patients. These cellular vaccines present and enhance immunogens, which will elicit a potent immune response. The goal is to achieve safe and effective immune reaction against the patient's own tumour. (1) Autologous cellular vaccines are prepared by processing circulating blood mononuclear cells outside of the patient's body (ex vivo) to differentiate them into antigen-presenting cells (APCs). Monocyte-derived APCs (MD-APCs) are then grown in the presence of exogenous target antigens (tumour cell debris, or apoptotic bodies) to become fully mature APCs. (2) Functionality for antigen presentation to T cells of ex vivo MD-APCs is evaluated in vivo. (3) Cellular vaccines are tested in selected rodent animal models. Efficiency and immune response are monitored in pertinent experimental systems for cancer. Pharmacological data are generated for clinical investigation. Tolerance and biologic effects are documented in primates. (4) The first clinical trials on cancer patients are taking place in 1998 on melanoma and prostate cancer to validate the concept. Specialized cell processors with dedicated software and standardized controls are being developed and used for the preparation of cellular vaccines. (5) The evaluation of new non-viral vectors and the validation of new non-viral transfection methods of mononuclear cells with marker genes is in progress and will lead to the ex vivo transfection of genes coding for immunostimulating cytokines or for tumour antigens in MD-APCs. Efficiency will be validated in vitro and in animal models. The ex vivo and animal model studies validate the clinical relevance of this new cellular immunotechnology. Clinical validation of individual autologous cellular vaccines in specific indications for which no treatment is presently available will allow the development of cellular and gene immunotherapy for other types of cancers.
authors.affiliation: IDM, Paris, France.
authors.forename: J
authors.initials: J
authors.lastname: Bartholeyns
authors.forename: J L
authors.initials: JL
authors.lastname: Romet-Lemonne
authors.forename: M
authors.initials: M
authors.lastname: Chokri
authors.forename: M
authors.initials: M
authors.lastname: Buyse
authors.forename: T
authors.initials: T
authors.lastname: Velu
authors.forename: C
authors.initials: C
authors.lastname: Bruyns
authors.forename: J J
authors.initials: JJ
authors.lastname: Van de Winkel
authors.forename: J
authors.initials: J
authors.lastname: Heeney
authors.forename: G
authors.initials: G
authors.lastname: Koopman
authors.forename: M
authors.initials: M
authors.lastname: Malmsten
authors.forename: D
authors.initials: D
authors.lastname: De Groote
authors.forename: M
authors.initials: M
authors.lastname: Monsigny
authors.forename: P
authors.initials: P
authors.lastname: Midoux
authors.forename: B
authors.initials: B
authors.lastname: Alarcon
mesh_terms: D000818:Animals; D000938:Antigen-Presenting Cells / Q000166:cytology / Q000276:immunology*; D019496:Cancer Vaccines / Q000276:immunology*; D002986:Clinical Trials as Topic; D005822:Genetic Vectors; D006801:Humans; D008297:Male; D008545:Melanoma / Q000517:prevention & control; D009000:Monocytes / Q000166:cytology / Q000276:immunology*; D011471:Prostatic Neoplasms / Q000517:prevention & control; D013601:T-Lymphocytes / Q000276:immunology*
chemical_list: D019496:Cancer Vaccines